Navigation Links
Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial
Date:12/9/2008

com/prereg/key.process?key=PKCEC99FG.

To access the live conference call via phone, dial 888-713-4214. International callers may access the live call by dialing 617-213-4866. The reference number to enter the call is 61907318.

The replay of the conference call may be accessed via the Internet, at http://www.alexza.com, or via phone at 888-286-8010 for domestic callers or 617-801-6888 for international callers. The reference number for the replay of the call is 85181265.

About Acute Agitation

Acute agitation affects many people suffering from major psychiatric disorders, including schizophrenia and bipolar disorder. Patients experiencing agitation become uncomfortable, tense, and restless, and as the agitation intensifies, patients can become threatening and violent if the agitation is not treated.

Based on the Company's analysis of patient information from the National Institute of Mental Health (NIMH), the company believes that in the United States schizophrenia afflicts about 2.5 million adults and bipolar disorder affects about 6 million adults. The Company believes approximately 90% of these patients experience agitation at some point during their lifetime, and more than two-thirds of this group will suffer at least one episode -- and often up to six episodes -- of agitation every year, with about half of the cases requiring hospitalization.

Agitation is currently treated with injectable and oral anti-psychotic medications: the oral medications work relatively slowly and while the intramuscular injections have a faster onset of action, they are invasive and can be frightening to patients. The American Association of Emergency Psychiatrists published the Expert Consensus Guidelines for the Treatment of Behavioral Emergencies in 2001, which state three key treatment attributes for choosing treatment f
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Alexzas AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
2. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
3. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
4. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
5. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
8. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
9. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
10. TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
11. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Harvard medical expert internationally recognized as a leading ... decision last month to suspend Doug Barron for ... having the medical condition hypogonadism and ... unfair and discriminatory." ,, Hypogonadism is ... often referred to informally as Low T ...
(Date:12/15/2009)... -- Fenwal Inc., a global medical technology company ... availability, announced today that the U.S. Food and ... InterSol ® platelet additive solution. Fenwal ... specialized product used in combination with human plasma ... used to prevent or treat bleeding. ,, InterSol ...
(Date:12/15/2009)... -- Reportlinker.com announces that a new market ... ,, Boehringer Ingelheim GmbH: PharmaVitae Profile ... Introduction ,, This analysis examines the ... in the Rx pharmaceutical sector. The profile ... and assessment of financial performance, with 1-6 ...
Breaking Medicine Technology:Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 2Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 3Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 4Fenwal Receives FDA Approval for New Solution Used to Store Donated Blood Platelets 2Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 2Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 3Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 4Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 5Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 6Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 7Heart Attacks Less Often Fatal Today 49550 1Heart Attacks Less Often Fatal Today 49550 2Heart Attacks Less Often Fatal Today 49550 3EUROPACE raises remote monitoring profile 49546 1EUROPACE raises remote monitoring profile 49546 2EUROPACE raises remote monitoring profile 49546 3Governor Rendell Discusses Impact of Budget on Services for Families of Children With Autism 49543 1Governor Rendell Discusses Impact of Budget on Services for Families of Children With Autism 49543 2
... 28 Aida,Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) ... II field testing of its,anti-cancer drug, Rh-Apo2L. The ... intended to be a new drug therapy using ... is designed as a highly-targeted,therapy with direct function ...
... Initiate Phase III Program in First Half of ... Inc. (Nasdaq: IDEV ) today announced positive ... patients with acromegaly, a,disorder characterized by excessive blood ... factor 1 (IGF-1). The implant utilizes the Company,s,patented ...
Other Medicine Technology:Aida Announces Completion of Anti-Cancer Drug Phase Two Testing 2Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial 2Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial 3Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial 4Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial 5
(Date:12/15/2009)... -- Palo Alto Networks(TM), the network security company, ... PA-4000 Series next-generation firewalls for accurate threat prevention ... and control over applications such as peer-to-peer file ... university with eight facilities on five campuses. The ... number of academic schools and institutions throughout Japan. ...
(Date:12/15/2009)... the Lupus Foundation of America and the Saint Thomas, ... -- Julian Lennon, son of the legendary John Lennon, ... single, "LUCY," to raise funds for research on the ... percent of the proceeds from downloading "LUCY" at iTunes ... (LFA), and the Saint Thomas, Lupus Trust in Great ...
(Date:12/15/2009)... Dec. 15 Vitech Systems Group, a ... Management (CRM) software, announced today that it has ... for the Screen Actors Guild-Producers Pension & Health ... customer service capabilities to SAG-PH call center personnel ... was installed using Vitech,s V3 Benefits Administration System ...
(Date:12/15/2009)... associated with lower dementia risk, research finds , , TUESDAY, ... leptin, a hormone that regulates appetite, may guard against ... or 15 years this may be one of many ... Alzheimer,s disease," said senior study author Dr. Sudha Seshadri, ... of Medicine. "Or it may be one of many ...
(Date:12/15/2009)... doses have lower strength than needed for protection, CDC ... 800,000 children,s doses of H1N1 swine flu vaccine have ... have lost some potency, federal health officials said Tuesday. ... and Prevention, the company,s routine testing of the vaccine ... found that four batches had lower than required potency ...
Breaking Medicine News(10 mins):Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 2Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 3Health News:Julian Lennon and James Scott Cook Release New Charity Single 'LUCY' to Raise Awareness and Funds for Lupus Research 2Health News:Screen Actors Guild - Producers Pension & Health Plans Live on New CRM Solution 2Health News:Fat Hormone May Protect Against Alzheimer's 2Health News:Fat Hormone May Protect Against Alzheimer's 3Health News:Large Recall of Children's Swine Flu Vaccine 2
... NxStage Medical, Inc. (Nasdaq: NXTM ), a leading ... its financial results for the fourth quarter and full year ... the opening of the financial markets.NxStage will also host a ... 12, 2009 to discuss its fourth quarter and year end ...
... Former Director of National Institutes of HealthNEW YORK, Feb. 3 ... today the election of Dr. Elias A. Zerhouni , ... and leader in biomedical research, to its Board of Directors."We ... Board of Directors," said Dr. Maria C. Freire , ...
... Chief Marketing Officer and PACS Industry Veteran ... Feb. 3 Compressus, Inc., leaders in healthcare ... with the promotion of Janine Broda to chief ... Gibbons as vice president and general manager of ...
... Female Health Company (NYSE Alternext: FHC) today announced that ... its operating results for the first quarter of FY2009 ... 10, 2009. The Company plans to report its ... and other interested parties may participate in the conference ...
... Healthy, Inc. (Pink Sheets: GOHE) announced today that the ... development of major sports relationships at meetings held in ... partnership with a sports entity, whose members are among ... a major extension of our agreement with Athletic International ...
... best way of spotting trouble, experts say , , TUESDAY, ... stool-based colon cancer tests -- recommended annually for Americans ... spot potential abnormalities, a German study finds. , Doctors ... for what is called fecal occult blood -- otherwise ...
Other Medicine News:Health News:NxStage to Report Fourth Quarter and Full Year 2008 Financial Results 2Health News:Lasker Foundation Welcomes Elias Zerhouni to Board of Directors 2Health News:Compressus Bolsters Executive Team to Expand Interoperability Market Pioneered by MEDxConnect(TM) 2Health News:Compressus Bolsters Executive Team to Expand Interoperability Market Pioneered by MEDxConnect(TM) 3Health News:The Female Health Company Schedules First Quarter Conference Call for February 10, 2009 2Health News:Go Healthy Participates in Super Bowl Events and Developing Sports Relationships 2Health News:Stool-Based Colon Cancer Tests Vary Widely in Accuracy 2Health News:Stool-Based Colon Cancer Tests Vary Widely in Accuracy 3
... are the latest innovation ... portable battery-powered EEG headboxes. ... new mechanical design, and ... standard MOBEE24plus and MOBEE32 ...
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
Medicine Products: